Precision and translational neurology: From mechanistic insight to personalised care

© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

XML

Cite

Conflict of interest

Kheng-Seang Lim is a member of the Editorial Board of this journal but was not involved, either directly or indirectly, in the editorial decision-making or peer-review process for this manuscript. The other author declares no conflict of interest.

References

GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344-381. doi: 10.1016/S1474-4422(24)00038-3
Hampel H, Gao P, Cummings J, et al. The foundation and architecture of precision medicine in neurology and psychiatry. Trends Neurosci. 2023;46(3):176-198. doi: 10.1016/j.tins.2022.12.004
Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037. doi: 10.1056/NEJM200104053441401
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. doi: 10.1056/NEJM200103153441101
Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413-2421. doi: 10.1038/s41436-019-0554-6
Tijms BM, Vromen EM, Mjaavatten O, et al. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4(1):33-47. doi: 10.1038/s43587-023-00550-7
Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi: 10.1001/jama.2020.12134
Mathys H, Davila-Velderrain J, Peng Z, et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature. 2019;570(7761):332-337. doi: 10.1038/s41586-019-1195-2
Wang NN, Cao F, Zhang LH, Zheng YF, Xu D. Multi-omics: a bridge connecting genotype and phenotype for epilepsy? Biomark Res. 2025;13(1):86. doi: 10.1186/s40364-025-00798-8
Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722. doi: 10.1056/NEJMoa1706198
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. doi: 10.1056/NEJMoa1716153
Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099-1110. doi: 10.1056/NEJMoa2204705
Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2):165-174. doi: 10.1001/jama.2018.18743
Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5. doi: 10.1038/s41392-022-01278-3
Dorsey ER, Glidden AM, Holloway MR, et al. Teleneurology and mobile technologies: the future of neurological care. Nat Rev Neurol. 2018;14(5):285–297. doi: 10.1038/nrneurol.2018.31
Tveit J, Aurlien H, Plis S, et al. Automated interpretation of clinical electroencephalograms using artificial intelligence. JAMA Neurol. 2023;80(8):805-812. doi: 10.1001/jamaneurol.2023.1645
Servais L, Yen K, Guridi M, et al. Stride velocity 95th centile: insights into gaining regulatory qualification of the first wearable-derived digital endpoint for use in Duchenne muscular dystrophy trials. J Neuromuscul Dis. 2022;9(2):335-346. doi: 10.3233/JND-210743
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62-70. doi: 10.1056/NEJMra1510062
Marshall SF, Burghaus R, Cosson V, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93-122. doi: 10.1002/psp4.12049
Romero K, Ito K, Rogers JA, et al. The future is now: model-based clinical trial design for Alzheimer’s disease. Clin Pharmacol Ther. 2015;97(3):210-214. doi: 10.1002/cpt.16
Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840-842. doi: 10.1038/453840a
Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6

Previous article in this issue

Next article in this issue

Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing